TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10526909

Group type: EXPERIMENTAL
Intervention: Framingham criteria
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: De Simone et al. criteria
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Cornell‐Penn criteria
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Framingham or De Simone et al. criteria
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Eccentric hypertrophy
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Concentric remodelling
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: No evidence of left ventricular structural alterations
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Age, gender, systolic blood pressure, pulse pressure, body mass index
Number of subjects: 946
Study: 7723649

Group type: EXPERIMENTAL
Intervention: Simulated climbing
Number of subjects: 11

Group type: COMPARATOR
Intervention: Treadmill running
Number of subjects: 11

Group type: COMPARATOR
Intervention: Rowing ergometry
Number of subjects: 11
Study: 1675329

Group type: EXPERIMENTAL
Intervention: Occupational therapy home service (6-week comprehensive programme)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (no treatment for 6 weeks)
Number of subjects: 105
Study: 7026020

Group type: EXPERIMENTAL
Intervention: CMFP (cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone)
Number of subjects: 51

Group type: COMPARATOR
Intervention: VAC (vincristine, Adriamycin, and cyclophosphamide)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CMFP
Number of subjects: 51

Group type: COMPARATOR
Intervention: VAC
Number of subjects: 51
Study: 30943735

Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 281

Group type: COMPARATOR
Intervention: Standard oncologic care (SOC)
Number of subjects: 281
Study: 29411520

Group type: EXPERIMENTAL
Intervention: Moisturizer containing 4-t-butylcyclohexanol and licochalcone A
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.02% triamcinolone acetonide cream
Number of subjects: 80
Study: 26932305

Group type: COMPARATOR
Intervention: Vildagliptin/metformin FDC tablets (50/250 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vildagliptin/metformin FDC tablets (50/500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin FDC tablets (50/500 mg) after meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin under fed condition
Number of subjects: 0
Study: 24699052

Group type: EXPERIMENTAL
Intervention: 200 mg mixed tocotrienols twice a day for 2 years
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 22616928

Group type: EXPERIMENTAL
Intervention: Ceram X mono
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ceram X mono + Ribbond
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek P90
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Filtek P90 + Ribbond
Number of subjects: 80
Study: 21034895

Group type: EXPERIMENTAL
Intervention: Large-capacity forceps
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Standard forceps
Number of subjects: 65

Group type: COMPARATOR
Intervention: Jumbo forceps
Number of subjects: 65
Study: 17488783

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychodynamic interpersonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antispasmodics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ispaghula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT4 agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors
Number of subjects: 0
Study: 16084157

Group type: EXPERIMENTAL
Intervention: eptifibatide + tenecteplase (0.25 mg/kg intravenous bolus)
Number of subjects: 148

Group type: COMPARATOR
Intervention: eptifibatide + placebo
Number of subjects: 148
Study: 12373040

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) consisting of transdermal application of continuous 17beta‐estradiol with cyclic medroxyprogesterone acetate (MPA) tablets for 14 days every 3rd month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10197835

Group type: EXPERIMENTAL
Intervention: Pindolol (2.5 mg 3 times daily) for 10 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (3 times daily) for 10 days
Number of subjects: 80
Study: 7572723

Group type: EXPERIMENTAL
Intervention: Yogurt containing active cultures
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Pasteurized yogurt
Number of subjects: 14

Group type: COMPARATOR
Intervention: Milk
Number of subjects: 14
Study: 2179850

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin E (dl-alpha-tocopherol) on days 1, 2, 4, and 6 of life
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intramuscular placebo injections on the same schedule
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Vitamin E treatment in survivors
Number of subjects: 149
Study: 7247587

Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with chlorthalidone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with hydrochlorothiazide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate sodium diet with furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher sodium diet with chlorthalidone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher sodium diet with hydrochlorothiazide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Higher sodium diet with furosemide
Number of subjects: 12
Study: 31455085

Group type: EXPERIMENTAL
Intervention: Group education
Number of subjects: 300

Group type: COMPARATOR
Intervention: Individual education
Number of subjects: 300
Study: 30281813

Group type: EXPERIMENTAL
Intervention: Tooth brushing once daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Tooth brushing twice daily
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Tooth brushing three times daily
Number of subjects: 345
Study: 27894329

Group type: EXPERIMENTAL
Intervention: Early controlled motion of the ankle in weeks 3-8 after rupture
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (immobilization)
Number of subjects: 130
Study: 24219618

Group type: EXPERIMENTAL
Intervention: High-dose paracetamol (40 mg/kg body weight, max 2000 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: High-dose paracetamol
Number of subjects: 51
Study: 22948036

Group type: EXPERIMENTAL
Intervention: UDCA (13‐15 mg/kg/day for 4 weeks)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 20739431

Group type: EXPERIMENTAL
Intervention: Bortezomib after high-dose melphalan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Bortezomib before high-dose melphalan
Number of subjects: 39
Study: 18188757

Group type: EXPERIMENTAL
Intervention: Night smoking
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy overnight
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Treatments that improve sleep quality
Number of subjects: 691
Study: 15745651

Group type: EXPERIMENTAL
Intervention: COG‐AFF (mismatched to affective)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AFF‐COG (mismatched to cognitive)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: COG‐COG (matched cognitive)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AFF‐AFF (matched affective)
Number of subjects: 100
Study: 12532389

Group type: EXPERIMENTAL
Intervention: Submicron oil-in-water (o/w) emulsion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semisolid water-in-oil (w/o) emulsion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 15 min application time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60 min application time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 240 min application time
Number of subjects: 0
Study: 10723849

Group type: EXPERIMENTAL
Intervention: CMCA intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (age 21 and over)
Number of subjects: 15
Study: 9196769

Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg weekly
Number of subjects: 624

Group type: COMPARATOR
Intervention: Chloroquine 300 mg weekly and proguanil 200 mg daily
Number of subjects: 624
Study: 1330396

Group type: EXPERIMENTAL
Intervention: Treatment A (solution, fasted)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment B (capsule with food)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Treatment C (capsule without food)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment A
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment B
Number of subjects: 12

Group type: COMPARATOR
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment C
Number of subjects: 12
Study: 4068909

Group type: COMPARATOR
Intervention: Moderate fat formula diet (32% energy as corn oil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low fat formula diet (9% fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Very low fat formula diet (1-3% fat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low and very low fat formulas (ingested for three weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate fat formula diet (high P/S ratio)
Number of subjects: 0
Study: 31342474

Group type: EXPERIMENTAL
Intervention: 19 G Franseen-tip core biopsy needle (FNB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 19 G aspiration needle (FNA)
Number of subjects: 40
Study: 29852863

Group type: EXPERIMENTAL
Intervention: Omega-3 (300 mg daily)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 160
Study: 26513023

Group type: EXPERIMENTAL
Intervention: eDST (electronic decision support tool)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (using any resource in addition to the app)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: eDST
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (using cognitive aids)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: eDST and Control
Number of subjects: 259
Study: 24898101

Group type: EXPERIMENTAL
Intervention: Early oral antibiotic switch (group A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional intravenous antibiotics (group B)
Number of subjects: 59
Study: 22940436

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K6 cigarette (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K3 cigarette (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Philip Morris One cigarettes (1mg tar, 0.1mg nicotine, and 2.0mg CO)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 160

Group type: COMPARATOR
Intervention: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Number of subjects: 160
Study: 19965667

Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo SCT)
Number of subjects: 84
Study: 18294729

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (3 L/minute)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Compressed air (room air)
Number of subjects: 110
Study: 15839920

Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg
Number of subjects: 1059

Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study: 12691375

Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 11590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11590

Group type: EXPERIMENTAL
Intervention: CK-MB values >10 times the upper limit of normal
Number of subjects: 11590
Study: 11798671

Group type: EXPERIMENTAL
Intervention: Captopril (12.5mg three times daily)
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1376
Study: 8923833

Group type: EXPERIMENTAL
Intervention: hCRH (0.4 microgram/kg) and NAL (65 micrograms/kg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MET pretreatment plus CRH/NAL
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: NAL
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo pretreatment plus CRH/NAL stimulation
Number of subjects: 11

Group type: COMPARATOR
Intervention: MET alone
Number of subjects: 11
Study: 1746790

Group type: EXPERIMENTAL
Intervention: Ranitidine elixir 3 mg/kg via nasogastric tube every 12 hours
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intravenous (IV) ranitidine 1 mg/kg every 8 hours
Number of subjects: 36
Study: 6700849

Group type: EXPERIMENTAL
Intervention: Single 2-g preoperative dose of cefoxitin
Number of subjects: 112

Group type: COMPARATOR
Intervention: Three 2-g doses of cefoxitin over 12 hours
Number of subjects: 112
Study: 29948596

Group type: EXPERIMENTAL
Intervention: Essential oil treatment applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Almond placebo oil control group applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Number of subjects: 70
Study: 30275687

Group type: EXPERIMENTAL
Intervention: 24-week multicomponent intervention (group exercise, nutritional supplementation, depression management, deprescribing medications, home hazard reduction)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 24-week multicomponent intervention
Number of subjects: 187
Study: 27627192

Group type: EXPERIMENTAL
Intervention: AZD1305 + ketoconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD1305 + verapamil
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZD1305 alone
Number of subjects: 0
Study: 24393349

Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Sham or PDT
Number of subjects: 1125
Study: 21343348

Group type: EXPERIMENTAL
Intervention: Etamicastat (2, 10, 20, 50, 100, 200, 400, 600, 900, or 1200 mg)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Etamicastat (100 mg and above)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etamicastat
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acetylated metabolite of etamicastat
Number of subjects: 80
Study: 20339359

Group type: EXPERIMENTAL
Intervention: Weight reduction (BMI reduction by 1 SDS, n = 51; and 2 SDS, n = 21) under conservative treatment for 18 months.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sustained weight reduction for 6 months after initial weight loss.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Not applicable (control group of healthy prepubertal children).
Number of subjects: 70
Study: 22901116

Group type: EXPERIMENTAL
Intervention: Multi-professional Intervention and Training for Ongoing Volunteer-based Community Health Programme
Number of subjects: 2045
Study: 15901395

Group type: EXPERIMENTAL
Intervention: Exclusive, smaller gift items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less luxurious, more useful gifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gift vouchers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cash gifts
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Separate evaluations of gifts
Number of subjects: 0
Study: 12358231

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 67

Group type: COMPARATOR
Intervention: Patients with symptomatic gallstones
Number of subjects: 67
Study: 10469705

Group type: EXPERIMENTAL
Intervention: Group culture in a small volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single culture in a small volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single culture in a large volume
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group culture in a large volume
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 8912492

Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 100
Study: 1744867

Group type: EXPERIMENTAL
Intervention: 10 mg timolol orally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6750167

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 683

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 683
Study: 30045259

Group type: COMPARATOR
Intervention: Melatonin (ML)
Number of subjects: 88

Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 88
Study: 27334116

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (nine-session psychoeducational program)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Family Foundations intervention
Number of subjects: 399

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 399
Study: 26162825

Group type: EXPERIMENTAL
Intervention: EVICEL™ applied during surgery (5 ml)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Electrocoagulation (standard treatment)
Number of subjects: 68
Study: 23024015

Group type: COMPARATOR
Intervention: golimumab 100 mg
Number of subjects: 356

Group type: COMPARATOR
Intervention: golimumab 50 mg
Number of subjects: 356
Study: 20673353

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (28 day cycles of cyclophosphamide, methotrexate and 5‐fluorouracil)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 322

Group type: COMPARATOR
Intervention: Control (no specific treatment mentioned)
Number of subjects: 322
Study: 18486740

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks (for partial responders)
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks (for partial responders)
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (for partial responders)
Number of subjects: 1230
Study: 16901250

Group type: EXPERIMENTAL
Intervention: bio-psychosocial approach including virtual reality
Number of subjects: 211
Study: 12531444

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g IV at induction of anesthesia)
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Cefotaxime (1 g IV at induction of anesthesia)
Number of subjects: 1013
Study: 11064186

Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 0 mg naloxone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 4 mg naloxone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 8 mg naloxone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine + naloxone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Buprenorphine bioavailability
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Naloxone bioavailability
Number of subjects: 9
Study: 8673309

Group type: EXPERIMENTAL
Intervention: Topically applied recombinant human platelet‐derived growth factor (rhPDGF)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 118
Study: 2052484

Group type: EXPERIMENTAL
Intervention: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7101088

Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g, intramuscularly)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 x 10^6 units) plus probenecid (1.0 g)
Number of subjects: 83
Study: 30209152

Group type: EXPERIMENTAL
Intervention: Oral TN-TC11M (THC 2.5mg/CBD 2.5mg) capsules
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80
Study: 27871549

Group type: EXPERIMENTAL
Intervention: Epidural chloroprocaine 1.2% mixed with 0.4μg/mL fentanyl
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Epidural chloroprocaine (0.6%, 0.8%, 1.0%, 1.2%, 1.4%)
Number of subjects: 120
Study: 25826885

Group type: EXPERIMENTAL
Intervention: Lateral tibiofemoral joint 90° flexional gap measurement resection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional osteotomy (control group)
Number of subjects: 60
Study: 22457736

Group type: EXPERIMENTAL
Intervention: Sleep after learning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wakefulness after learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep preceding wakefulness
Number of subjects: 0

Group type: COMPARATOR
Intervention: 12 hr of waking interference
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sleep at 24 hr retest
Number of subjects: 0
Study: 20378307

Group type: EXPERIMENTAL
Intervention: Single‐incision modified Smith‐Peterson approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 18795916

Group type: EXPERIMENTAL
Intervention: V. filiformis cream 5%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 75
Study: 16176175

Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine treatment
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: didanosine+stavudine treatment
Number of subjects: 232

Group type: COMPARATOR
Intervention: Comparison between zidovudine+lamivudine and didanosine+stavudine
Number of subjects: 232
Study: 12136395

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg once daily for 6 weeks)
Number of subjects: 20
Study: 10447629

Group type: EXPERIMENTAL
Intervention: Classic nail (intramedullary implant) for fixation of peritrochanteric fractures
Number of subjects: 85
Study: 7493234

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.006%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20